Sienna Biopharmaceuticals acquires drug candidates for treating psoriasis, atopic dermatitis

Sienna Biopharmaceuticals announced it has acquired Creabilis plc, a specialty pharmaceutical company focused on developing topical treatments for inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus.

Among the first-in-class and late-stage and patented clinical candidates acquired by Sienna are SNA-120, a phase IIb topical tropomyosin receptor kinase A (TrkA) inhibitor former known as CT327, for treating pruritus and psoriasis; and SNA-125, a topical TrkA/Janus kinase 3 inhibitor formerly known as CT327, for treating atopic dermatitis, psoriasis and pruritus, according to a press release.

Creabilis developed the new drug candidates through a proprietary “topical by design” platform, which also includes pre-clinical drug candidates developed through the technology.

As part of the acquisition, Sienna will make an undisclosed upfront payment in cash and stocks, as well as payments contingent upon achieving regulatory and commercial milestones, which could all exceed $150 million, according to the release.

Reference: www.siennabio.com